CN107137427A - The new application of pseudomonas aeruginosa - Google Patents
The new application of pseudomonas aeruginosa Download PDFInfo
- Publication number
- CN107137427A CN107137427A CN201710483519.3A CN201710483519A CN107137427A CN 107137427 A CN107137427 A CN 107137427A CN 201710483519 A CN201710483519 A CN 201710483519A CN 107137427 A CN107137427 A CN 107137427A
- Authority
- CN
- China
- Prior art keywords
- pseudomonas aeruginosa
- neck
- postoperative
- purposes according
- drainage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses purposes of the pseudomonas aeruginosa in the art for prepare Neck dissections in adjuvant drug.P. aeruginosa bacteria preparation can dramatically speed up the postoperative quick recovery of Neck dissections, and using safe and reliable, provide a kind of new medicament selection for clinical thyroid cancer auxiliary treatment, application prospect is good.
Description
Technical field
The invention belongs to microbe application field, and in particular to the new application of pseudomonas aeruginosa.
Background technology
Thyroid cancer is most common thyroid malignancy, from Thyroid follicular epithelial cell, and the incidence of disease is in recent years
Explosive growth.The transfer of cervical lymph node, especially thyroid papillary carcinoma (PTC) easily occur for thyroid cancer, and lymph is carried down
Shifting rate is up to 80%, and the incidence of micrometastasis is more up to 90%.Once metastasic cervical lymph nodes occur will increase postoperative multiple
Send out risk and the postoperative long term survival of patient.
Neck dissections are en bloc resection cervical lymph tissue and fat, muscle, nerve, the blood vessel of surrounding etc.,
It is widely used in treating cervical metastatic cancer.Thyroid cancer occurs after metastasic cervical lymph nodes, dissection operation
Treatment to thyroid cancer patients is particularly important, directly affects the sick successive treatment and follow-up, and closely related with prognosis, beautiful
Endocrine association of state advises Neck dissections as the standard processing mode of thyroid cancer.
The most common metastasis sites of thyroid cancer PTC are central lymph node (VI areas), next to that side neck region II-V areas are drenched
Fawn on transfer report and be also up to 30-40%.Central lymph node dissection is compared to, lateral areas lymph node dissection seems and more attached most importance to
Will：First, central lymph node at present recommend to carry out preventative cleaning by most of guide, and lateral areas lymph node only recommends treatment
Property clean, so be easier omission lateral areas；Secondly, lateral areas lymph node is shifted, and case is N1b by stages, and its prognosis will be by
To significantly affecting：Postoperative recurrence risk substantially increases；Furthermore, lateral areas scope is big, and range of operation is wide, lymph node dissection operating difficulty
Greatly, incidence of complications is higher：It is common such as postoperative hemorrhage (its incidence may be up to 3.3-10.5%), lateral areas Lymphatic Fistulas
(its incidence may be up to 8.3-13.5%), these complication managements are difficult, and treatment cycle is long, or even needs second operation.
Pseudomonas aeruginosa (P.Aeruginosa) original claims Pseudomonas aeruginosa.In distributed in nature extensively, it is to exist in soil
One of most common bacterium.It is a variety of in stomach cancer, breast cancer, carcinoma of urinary bladder, cervical carcinoma etc. that P. aeruginosa bacteria preparation is had at present
The report of immunization therapy is participated in malignant tumour, it can increase the chemotherapy ability to bear of patient, mitigate the toxic side effect of chemotherapy,
It is widely used in the auxiliary treatment of malignant tumour.
The content of the invention
It is an object of the invention to provide the new application of pseudomonas aeruginosa.
The invention provides use of the pseudomonas aeruginosa in the art for prepare Neck dissections in adjuvant drug
On the way.It is described present invention also offers purposes of the pseudomonas aeruginosa in the adjuvant drug of Neck dissections is prepared
Adjuvant drug is the bleeding of prevention of postoperative drainage-fluid, postoperative Lymphatic Fistulas, reduces drainage flow, and/or drainage tube pulls out the time ahead of time
Medicine.
In art：Refer to the agent-feeding treatment after whole surgical procedure, including Neck dissections, placement drainage tube.
Wherein, the Neck dissections are neck lateral areas Pulmonary resections.
Wherein, the Neck dissections are thyroid cancer Neck dissections.
Wherein, the thyroid cancer Neck dissections are thyroid cancer neck lateral areas Pulmonary resections.
Wherein, the adjuvant drug is the bleeding of reduction postoperative drainage liquid, postoperative Lymphatic Fistulas, reduces drainage flow, and/or carry
Early drainage tube pulls out the medicine of time.
Wherein, the medicine is, to inactivate pseudomonas aeruginosa as active ingredient, to add pharmaceutically conventional auxiliary material and prepare
Preparation.
Wherein, the preparation is ejection preparation or external preparation；Wherein, the preparation is pseudomonas aeruginosa injection.
Wherein, in the pseudomonas aeruginosa injection, every milliliter of 1.6-2.0X containing pseudomonas aeruginosa 109It is individual.
Wherein, the pseudomonas aeruginosa injection is prepared from by following methods：Take pseudomonas aeruginosa MSHA pili
Strain, culture, inactivation, purifying, add PBS dilution, you can.
It is a discovery of the invention that in thyroid cancer patients neck lateral areas Radical dissection, by using inactivation P. aeruginosa in art area
Bacterium, can substantially reduce postoperative drainage liquid measure, significantly shorten pulling out the time, substantially reducing postoperative hemorrhage and Lymphatic Fistulas hair for drainage tube
It is raw, so as to effectively accelerate the postoperative quick recovery of patient, shorten post-operative hospital stay, and be clinical first shape using safe and reliable
Gland cancer auxiliary treatment provides a kind of new medicament selection, and potential applicability in clinical practice is good.
Obviously, according to the above of the present invention, according to the ordinary technical knowledge and customary means of this area, do not departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification of other diversified forms can also be made, replaces or changes.
The embodiment of form, remakes further specifically to the above of the invention by the following examples
It is bright.But the scope that this should not be interpreted as to above-mentioned theme of the invention is only limitted to following example.It is all to be based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Brief description of the drawings
50 neck lateral areas of Fig. 1 clean total drainage of preventive use inactivation pseudomonas aeruginosa injection group (experimental group)
Amount is considerably less than control group (p=0.048).
The postoperative extubation time of Fig. 2 experimental groups and post-operative hospital stay are significantly shorter than control group (P<0.05).
Red blood cell count(RBC) is significantly lower than control group (P in Fig. 3 experimental group postoperative drainage liquid<0.05).
Triglyceride levels are significantly lower than control group (P in Fig. 4 experimental group postoperative drainage liquid<0.05).
The postoperative day highest body temperature of Fig. 5 experimental group patients and control group indifference (P>0.05).
Fig. 6 experimental group patients postoperative pain (after static or activity) and the equal indifference (P of control group>0.05).
Embodiment
Beneficial effects of the present invention are illustrated below by way of test example：
Postoperative clinical observation on the therapeutic effect of the pseudomonas aeruginosa of test example 1 to thyroid cancer neck lateral areas Radical dissection
The inactivation pseudomonas aeruginosa injection that the present invention is used is purchased from Beijing Wanteer Biopharmaceutical Co., Ltd, also may be used
Pseudomonas aeruginosa (MSHA pilus strains) is voluntarily used to be formed by cultivating, inactivating, after purification with PBS dilution.
The single centre of the present invention, randomized controlled clinical experiment, have been obtained for Huaxi Hospital Attached to Sichuan Univ Ethics Committee
Approval, also Chinese Clinical experiment registration (number of registration：ChiCTR-IOR-17010605),
First, experimental method
1st, general information：
100 thyroid cancer patients in October, 2016 in April, 2017 are chosen, all patients are preoperative to pass through puncture
Confirm that neck lateral areas lymph node has transfer, and need row side neck lymph dissection, preoperative signature informed consent form, then using meter
The random grouping-hierarchy method of calculation machine is grouped：Experimental group (50) and control group (50).
2nd, treatment method：
Experimental group gives inactivation pseudomonas aeruginosa injection 2ml lateral areas after side neck lymph dissection, placement drainage tube
Sprinkling is (mainly along jugular vein outside back edge and the L-shaped sprinkling of subclavian vein upper limb)；
Control group gives conventional placement drainage tube, and the surface of a wound does not give any other material.The placement of lateral areas drainage tube is unified
2cm punchings are drawn under " decolletage arc incision " outer rim otch, and internal drainage tube is reserved 5 side openings, put along clavicle horizontal plane
Put.
3rd, postoperative index collection：
Postoperative regular diet, extra haemostatic medicament is not given, when lateral areas drainage tube drainage-fluid is less than 30ml, pulls out drainage
Pipe.Red blood cell count(RBC), triglyceride level in the main collection daily lateral areas drainage tube drainage-fluid volume of patient and drainage-fluid, note
The daily highest body temperature of record, cervical pain after static and motion is assessed using VAS scorings respectively.For body temperature rise and pain,
We do not recommend hormone medicine control.
4th, statistical difference specific analysis：
Statistical analysis is carried out to experimental group and control group using SPSS17.0.
2nd, experimental result
1st, efficiency evaluation
See Fig. 1-4.
As a result show：Preventive use inactivates pseudomonas aeruginosa injection in thyroid cancer patients neck lateral areas Radical dissection,
Lateral areas drainage-fluid can be substantially reduced, and (see Fig. 1, postoperative lateral areas drainage-fluid is total, experimental group vs control groups：171.5±91.8vs
212.6 ± 115.7ml, P<0.05)；Accelerating the pulling out of drainage tube, (see Fig. 2, lateral areas drainage tube is pulled out the time, experimental group vs controls
Group：3.4 ± 1.0vs 4.2 ± 1.4 days, P<0.05), so as to accelerate post-operative recovery, post-operative hospital stay is reduced (postoperative see Fig. 2
Hospital stays, experimental group vs control groups：5.7 ± 1.5vs 6.5 ± 2.6 days, P<0.05).
Moreover, in the red blood cell count(RBC) of drainage-fluid first 2 days after surgery, experimental group is significantly lower than control group (P<0.05)
(see Fig. 3).
Meanwhile, drainage-fluid triglyceride levels the 1st day after surgery, experimental group is significantly lower than control group (P<0.05) (see
Fig. 3), if being defined as the Lymphatic Fistulas of clinical meaning with drainage-fluid triglyceride levels >=11.3mmol/L, experimental group has 10
Example (20.0%), control group has 18 (36.0%), and the two has significant difference (P=0.044, P<0.05).
Therefore, in thyroid cancer patients neck lateral areas Radical dissection, preventive use inactivates pseudomonas aeruginosa in art, can be with
Substantially reduce postoperative drainage liquid measure, significantly shorten pulling out the time, substantially reducing postoperative hemorrhage and Lymphatic Fistulas generation for drainage tube, from
And accelerate postoperative quick recovery, shorten post-operative hospital stay.
2nd, safety evaluatio
Meanwhile, observation patient postoperative body temperature and cervical pain are shown in Fig. 5-6.
The postoperative daily highest Temperature changing result of patient is shown in Fig. 5, it is seen then that continuous clinical follow 3 days, two groups of patient temperatures
It is showed no notable difference.
For the pain of the postoperative neck of patient, it is divided into inactive state and active state, as a result sees Fig. 6, experimental group is with compareing
The scoring of group Principle of Pain and indifference (P>0.05).
In addition, all 50 patients of experimental group, follow-up at least three month, do not observe the generation of other complication.
Therefore, in thyroid cancer patients neck lateral areas Radical dissection, preventive use inactivation pseudomonas aeruginosa is peace in art
Complete.
To sum up, in thyroid cancer patients neck lateral areas Radical dissection, the present invention in art area by using inactivation P. aeruginosa
Bacterium, can substantially reduce postoperative drainage liquid measure, significantly shorten pulling out the time, substantially reducing postoperative hemorrhage and Lymphatic Fistulas hair for drainage tube
Give birth to, so that accelerate the postoperative quick recovery of patient, and use is safe and reliable, and potential applicability in clinical practice is good.
Claims (10)
1. purposes of the pseudomonas aeruginosa in the art for prepare Neck dissections in adjuvant drug.
2. purposes of the pseudomonas aeruginosa in the adjuvant drug of Neck dissections is prepared, the adjuvant drug is
The bleeding of prevention of postoperative drainage-fluid, postoperative Lymphatic Fistulas, reduce drainage flow, and/or drainage tube pulls out the medicine of time ahead of time.
3. purposes according to claim 1 or 2, it is characterised in that：The Neck dissections are neck lateral areas lymph
Tie Radical dissection.
4. purposes according to claim 1 or 2, it is characterised in that：The Neck dissections are thyroid cancer neck
Portion's Pulmonary resections.
5. purposes according to claim 4, it is characterised in that：The thyroid cancer Neck dissections are thyroid gland
Cancer neck lateral areas Pulmonary resections.
6. purposes according to claim 1, it is characterised in that：The adjuvant drug is reduction postoperative drainage liquid bleeding,
Postoperative Lymphatic Fistulas, reduces drainage flow, and/or drainage tube pulls out the medicine of time ahead of time.
7. purposes according to claim 1 or 2, it is characterised in that：The medicine is to inactivate pseudomonas aeruginosa to have
Composition is imitated, the preparation that pharmaceutically conventional auxiliary material is prepared from is added.
8. purposes according to claim 7, it is characterised in that：The preparation is ejection preparation or external preparation；Wherein, institute
Preparation is stated for pseudomonas aeruginosa injection.
9. purposes according to claim 8, it is characterised in that：In the pseudomonas aeruginosa injection, every milliliter of cupric
Green pseudomonad 1.6-2.0X109It is individual.
10. purposes according to claim 8, it is characterised in that：The pseudomonas aeruginosa injection is by following method systems
It is standby to form：Pseudomonas aeruginosa MSHA pilus strains, culture, inactivation, purifying are taken, PBS dilution is added, you can.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710483519.3A CN107137427B (en) | 2017-06-22 | 2017-06-22 | Novel application of pseudomonas aeruginosa |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710483519.3A CN107137427B (en) | 2017-06-22 | 2017-06-22 | Novel application of pseudomonas aeruginosa |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107137427A true CN107137427A (en) | 2017-09-08 |
| CN107137427B CN107137427B (en) | 2020-09-04 |
Family
ID=59782896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710483519.3A Active CN107137427B (en) | 2017-06-22 | 2017-06-22 | Novel application of pseudomonas aeruginosa |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107137427B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112972499A (en) * | 2021-02-23 | 2021-06-18 | 成都市温江区人民医院 | Operation method for radically treating malignant tumor of breast surgery by pseudomonas aeruginosa and application thereof |
| CN114364787A (en) * | 2019-08-22 | 2022-04-15 | 四川大学 | Application of pseudomonas aeruginosa vaccine in respiratory system diseases |
-
2017
- 2017-06-22 CN CN201710483519.3A patent/CN107137427B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 魏涛等: "铜绿假单胞菌注射液治疗甲状腺癌颈部淋巴结清扫术后淋巴漏的临床分析", 《中国普外基础与临床杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114364787A (en) * | 2019-08-22 | 2022-04-15 | 四川大学 | Application of pseudomonas aeruginosa vaccine in respiratory system diseases |
| CN114364787B (en) * | 2019-08-22 | 2024-03-01 | 四川大学 | Application of pseudomonas aeruginosa vaccine in respiratory diseases |
| CN112972499A (en) * | 2021-02-23 | 2021-06-18 | 成都市温江区人民医院 | Operation method for radically treating malignant tumor of breast surgery by pseudomonas aeruginosa and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107137427B (en) | 2020-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pan et al. | Dachengqi decoction attenuates intestinal vascular endothelial injury in severe acute pancreatitis in vitro and in vivo | |
| Huang et al. | Enhanced recovery after surgery using uniportal video‐assisted thoracic surgery for lung cancer: A preliminary study | |
| CN107137427A (en) | The new application of pseudomonas aeruginosa | |
| CN103041341B (en) | Traditional Chinese medicine composition for curing tuberculous exadative pleurisy and preparation method thereof | |
| CN101058809B (en) | Use of humanization modified rat ING4 gene and adenovirus expression vectors in preparing medicine for treating lung cancer | |
| CN102283838B (en) | Application of ethoxysanguinarine to pharmacy | |
| CN102441168A (en) | Medicine composition containing apigenin, apigenin derivant and Bc1-2 inhibitor and application thereof in preparation of medicines capable of treating cancer | |
| Li | Clinical practice guidelines for the interventional treatment of advanced pancreatic cancer | |
| Highshaw et al. | Port-site metastasis: the influence of biology | |
| Yang et al. | A novel drainage strategy using chest tube plus pleural catheter in uniportal upper lobectomy: A randomized controlled trial | |
| CN102250904B (en) | Medicine for preventing and/or treating melanoma | |
| CN101979549B (en) | Gene medicament taking voltage-gated proton channel Hv1 as targeted locus for treatment of breast cancer | |
| CN105287888A (en) | Cherry tomato ferment nutrient solution and preparation method thereof | |
| CN105362314B (en) | A kind of new application of twocolor sealavander herb ethyl acetate extract | |
| CN108079032A (en) | Purposes of the pill of Eight Treasures in the drug for inhibiting stomach cancer malignant development is prepared | |
| CN101683380B (en) | Method for preparing irrigating solution with anti-tumor function | |
| Ma et al. | The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid‐/Late‐Stage Hepatocellular Carcinoma | |
| CN101310767A (en) | Cryosurgery anticancer antigen preparation and preparation method thereof | |
| CN107198688A (en) | Application of the traditional Chinese medicine monomer lycorine in treatment breast cancer medicines are prepared | |
| CN104622903A (en) | Stem cell preparation for resisting malignant melanoma and preparation method of stem cell preparation | |
| CN114767692A (en) | Combined medicine of demethylzelaronal and metformin | |
| CN104623101A (en) | Traditional Chinese medicine for treating cancer as well as preparation method and application of traditional Chinese medicine | |
| CN103845499B (en) | A kind of Chinese medicine composition for the treatment of chronic prostatitis | |
| CN104195139B (en) | Treat and prevent antisense dna sequence and its application of porcine reproductive and respiratory syndrome | |
| CN101204507B (en) | Tincture medicine for brandy nose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |